Extrait

This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib.

Critère d'inclusion

• ADVANCED RENAL CELL CARCINOMA

Pays

• Argentina
• Bulgaria
• Canada
• Chile
• Czech Republic
• France
• Hungary
• India
• Italy
• Poland
• Romania
• Russian Federation
• Serbia
• Ukraine
• United Kingdom
• United States

Liens

• nct
• ictrp